retatrutide triple agonist gip glp-1 glucagon phase 3 2025 First data, a Triumph of Science! Lilly's triple agonist achieves 16.8%

95% CI: 0.581.14)

RESULTS RNA FORMULAS ARE CLEAN - Non-GMO, gluten-free, dairy-free, excipient-free & vegan-friendly

While these gummies don't contain GLP-1 medications, they are designed to nutritionally support the metabolic pathways involved in satiety.

The study demonstrates that quantitative target engagement of dual agonists can be assessed by PET.

Taking GLP-1s during the first trimester of pregnancy does not appear to increase the risk of major adverse outcomes such as non-live birth, according to a new Harvard Chan School study.

Explore the potential benefits and risks of GLP-1 medications for people with inflammatory bowel dis